Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Rio Tinto invests $1.9 billion to expand Australian bauxite operations, production to begin in 2029

Rio Tinto invests $1.9 billion to expand Australian bauxite operations, production to begin in 2029

智通财经智通财经2026/10/22 23:20
Show original
Rio Tinto (RIO.US) Group will invest $1.9 billion to expand its bauxite mining operations in northern Australia and develop a large new mine to replace the output from existing resources that are gradually being depleted. In a statement released Friday, Rio Tinto said the Kangwinan bauxite project will succeed the output from the Andoom and Gove mines in the region. The project is scheduled to begin production in 2029, at which point Rio Tinto’s annual production capacity in northern Queensland will increase from 38 million tons to 44 million tons. The bauxite mined by Rio Tinto is refined into alumina and then sent to smelters to be processed into aluminum metal. Jérôme Pécresse, Chief Executive of Rio Tinto Aluminium and Lithium, stated in the release that the project “demonstrates Rio Tinto’s long-term commitment to the bauxite business.”
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%